A053030 Stock Overview
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BINEX Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,430.00 |
| 52 Week High | ₩18,480.00 |
| 52 Week Low | ₩7,240.00 |
| Beta | 0.47 |
| 1 Month Change | -2.26% |
| 3 Month Change | 31.28% |
| 1 Year Change | 31.67% |
| 3 Year Change | -45.52% |
| 5 Year Change | 26.10% |
| Change since IPO | 606.84% |
Recent News & Updates
BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk
Apr 17
We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings
Mar 22BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up
Feb 26Recent updates
BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk
Apr 17We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings
Mar 22BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up
Feb 26Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Mar 18If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today
Jan 28Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Dec 24Shareholder Returns
| A053030 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.4% | 2.9% | 2.1% |
| 1Y | 31.7% | 7.0% | 6.6% |
Return vs Industry: A053030 exceeded the KR Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: A053030 exceeded the KR Market which returned 6.6% over the past year.
Price Volatility
| A053030 volatility | |
|---|---|
| A053030 Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A053030's share price has been volatile over the past 3 months.
Volatility Over Time: A053030's weekly volatility has increased from 8% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 570 | Jung-Tak Moon | www.bi-nex.co.kr |
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The company’s products portfolio comprises bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd.
BINEX Co., Ltd. Fundamentals Summary
| A053030 fundamental statistics | |
|---|---|
| Market cap | ₩415.32b |
| Earnings (TTM) | ₩4.67b |
| Revenue (TTM) | ₩154.82b |
88.9x
P/E Ratio2.7x
P/S RatioIs A053030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A053030 income statement (TTM) | |
|---|---|
| Revenue | ₩154.82b |
| Cost of Revenue | ₩97.93b |
| Gross Profit | ₩56.90b |
| Other Expenses | ₩52.23b |
| Earnings | ₩4.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 151.04 |
| Gross Margin | 36.75% |
| Net Profit Margin | 3.02% |
| Debt/Equity Ratio | 25.8% |
How did A053030 perform over the long term?
See historical performance and comparison